Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 1996

View Archived Issues

New NK1 antagonists claimed by Takeda

Fujisawa transfers rights to analgesic product to Roxane

NDA submitted for breakthrough pain Rx

New light shed on an old drug: Morphine and its mechanism of action

Clinical trials with oral and topical BCX-34 in psoriasis

Novel antibacterial compound from Banyu

Agennix announces patent coverage for lactoferrin

ASA + ibuprofen combination effective in treating Listeria infection in mice

NDA filed for AmBisome

Twelfth approval for Abelcet

HIV protease inhibitors described by DuPont

Lead HIV protease inhibitor from ArQule

Collaborative combination drug trial to begin in HIV-infected patients

Viral load markedly reduced by Invirase + Norvir

Lilly to manufacture SangStat generic immunosuppressant

Aquila's pneumococcal immunotherapeutic enters clinical trials

Italian introduction for CellCept

Oral tolerance therapy for transplant rejection from AutoImmune to enter clinic

AltaRex licenses alkylating agent for North America

Phase I tolerability and safety reported for Agouron's AG-331

Gemzar introduced in Italy

Phase II results with DaunoXome in non-Hodgkin's lymphoma

First alternative to 5-FU controls disease progression in colorectal cancer

First chemotherapeutic drug approved for advanced hormone-refractory prostate cancer

Promising clinical trial results on Taxotere presented at ESMO meeting

Final phase II data presented for Biomira's therapeutic cancer vaccine

Antineoplastic tyrosine kinase inhibitors disclosed by Thomae

IND filed in Canada for Neovastat

Eisai discloses antitumor compounds

Potent new antitumor agents revealed by Takeda

Auragen receives breast cancer research grant

Patent coverage for Genta's BCL2-targeted antisense compounds

Cell Therapeutics signs development and licensing agreements for lisofylline

Salagen Tablets more effective given during radiation therapy

New formulation of amifostine covered by U.S. patent

ADIR claims new agents for treating bone resorption

Green Cross describes inhibitors of lipid oxidation

New hypolipidemic agents described by Nippon Zoki

Symphony receives grant related to HMG-CoA inhibitors

Obesity research collaboration announced by Novo Nordisk and Boehringer Ingelheim

New formulation of Leukine approved by FDA

Approval of diagnostic test for E. coli toxins

FDA confirms superiority of ThinPrep Pap Test

FDA approval for INCSTAR's second-generation diagnostic tests

Avitech/Fox Chase genome diagnostics collaboration

Searle awards research grant to University of Calgary

UPCI scientists discover potential lung and oral cancer markers

Novel breath test for H. pylori infection in phase I

Antipsychotic agents from Taisho

Dutch researcher reports potential CNS agents

Safer, more potent antipsychotic agents reported by HMR

New antidepressants with improved safety reported by BMS

CombiChem/Roche Bioscience drug discovery collaboration

Alanex and Aurora join forces to identify new lead compounds

Patent covers Advanced Magnetics' targeted drug delivery system

U.S. patents and suits related to transgenic mice producing human antibodies

Hitachi acquires U.S. biotech company

New company formed to discover novel cancer treatments

Gensia announces strategic combination to form new pharmaceutical company

Amrad product pipeline in review

Latest findings on the diagnosis and treatment of erectile dysfunction

Rx for Parkinson's disease from NeuroSearch/BMS enters phase II

AutoImmune's MS therapeutic in final stages of development

New MS treatment approved in Israel

IL-6 as a target for Alzheimer's disease drug design

Daiichi discloses cerebroprotective agents

Senju reports new compounds for treating allergic disorders

Sandoz OTC medications approved for cold symptoms

Nasacort AQ superior to or preferred over other allergy medications

More convenient formulation of Azmacort cleared for asthma prophylaxis

HLE inhibitors reported by Japan Tobacco

Dual ACE/NEP inhibitors from Fujisawa

Fujisawa describes ACE and/or NEP inhibitors

Endothelin antagonists claimed by E. Merck

Biovail licenses once-daily diltiazem

FDA approves once-daily antihypertensive combination

Chugai discloses antiischemic agents

Clinical trials update on nibentan, Russian antiarrhythmic drug

NEP and ECE inhibitors reported by Kali-Chemie

Human pharmacokinetic/pharmacodynamic studies on bosentan

Cypros acquires well-established Rx for esophageal varices

Hyal and The Hospital for Sick Children vascular disease collaboration

Ciba-Geigy describes trypsin/thrombin inhibitors

Preclinical and clinical pharmacological profile of efegatran

CAPRIE study demonstrates clopidogrel more effective than aspirin

OP-1 effective in renal failure

Natural anti-H. pylori compounds described by Terumo

Anti-H. pylori agents disclosed by Shiseido

New 5-HT3/5-HT4 antagonists from Synthelabo

Roberts to license Lilly gastrointestinal compounds

Therapeutic effect of Lilly antioxidant demonstrated in rat model of IBD

Provir effective in acute diarrhea

Promising clinical results for lamivudine in hepatitis

Hyperparathyroidism Rx from NPS effective in dialysis patients

Takeda describes potential antidiabetic agents

Imidazoline compound reported as lead for oral hypoglycemic agents

Wyeth-Ayerst withdraws diabetes drug from markets worldwide

PKC inhibitors from Lilly for various therapeutic indications

Vasomax enters pivotal trials

Lilly reports agents to treat menopause-related conditions

Second NDA submitted for Crinone

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...